Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in

Status Recruiting

Clinical Trial Summary

This study aims to examine whether providing tube feeding with a formula enriched with omega-3 fats is better than traditional standard tube feeding in terms of preserving nutritional status, improving immune function and reducing medical complications following major upper Gut cancer surgery.

Clinical Trial Description

Title A double blinded randomized controlled trial to investigate the effects of an enteral nutritional supplement enriched with Eicosapentaenoic acid on long term nutritional status post operatively specifically the maintenance of lean body mass, and its potential impact on quality of life as well as examining the stress response and immune function and in patients undergoing surgical treatment of esophageal cancer.

Investigational medicinal Product(s):

Prosure (Abbott Laboratories)

Comparator:

Ensure Plus (Abbott Laboratories)

Study Objectives To examine whether prolonged supplementation with a nutritional supplement enriched with Eicosapentaenoic acid is superior to standard nutritional products in terms of promoting anabolism and improving quality of life in patients undergoing surgical treatment of esophageal cancer.

Study Design - Prospective randomized controlled trial.

Primary Endpoints:

- Quality of life Scores using EORTC Questionnaires

- Nutritional status on day 21 post oesophagectomy and/or total gastrectomy(specifically lean body mass) and at out patient follow up

Secondary Endpoints:

- Effects on the immuno-inflammatory response to surgery

- Post operative Clinical outcome including SIRS, sepsis and organ failure ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00790140
Study type	Interventional
Source	University of Dublin, Trinity College
Contact	Aoife Ryan, PhD
Phone	+35314284452
Email	ryana1@tcd.ie
Status	Recruiting
Phase	Phase 4
Start date	July 2005
Completion date	July 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06006390` - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors	Phase 1/Phase 2
Terminated	`NCT01624090` - Mithramycin for Lung, Esophagus, and Other Chest Cancers	Phase 2
Recruiting	`NCT05787522` - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
Not yet recruiting	`NCT05542680` - Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer	N/A
Completed	`NCT03384511` - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.	Phase 4
Completed	`NCT00003864` - Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus	Phase 2
Recruiting	`NCT05491616` - Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study	Phase 2
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Completed	`NCT00199849` - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine	Phase 1
Completed	`NCT03756597` - PAN-study: Pan-Cancer Early Detection Study (PAN)
Completed	`NCT00400114` - Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer	Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Recruiting	`NCT04615806` - The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy	N/A
Active, not recruiting	`NCT04566367` - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer	N/A
Active, not recruiting	`NCT03962179` - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)	N/A
Terminated	`NCT01446874` - Prevention of Post-operative Pneumonia (POPP)	Phase 2/Phase 3
Completed	`NCT03468634` - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy	N/A
Active, not recruiting	`NCT02869217` - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors	Phase 1
Completed	`NCT02810652` - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection	N/A
Recruiting	`NCT01404156` - Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms